Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Buy” by Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $17.43.

Several analysts have recently commented on VYGR shares. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Wedbush lowered their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th.

Voyager Therapeutics Stock Up 2.7 %

VYGR opened at $6.75 on Monday. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72. The business has a 50 day moving average price of $6.55 and a two-hundred day moving average price of $7.61. The company has a market cap of $367.16 million, a PE ratio of -135.00 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. As a group, sell-side analysts expect that Voyager Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. Great Point Partners LLC purchased a new position in Voyager Therapeutics during the second quarter worth $12,668,000. Armistice Capital LLC increased its position in Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Voyager Therapeutics by 3.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock worth $9,702,000 after acquiring an additional 37,144 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock valued at $925,000 after acquiring an additional 2,030 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.